Filing search / Lineage Cell Therapeutics, Inc. / "Community"

Search information

Lineage Cell Therapeutics, Inc.

Companies

"Community"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

177 results

Newest first Best match first

DEF 14A

LCTX Lineage Cell Therapeutics, Inc.

Definitive proxy

in a manner that is supportive of the entire community in which we operate. Our Board and senior leadership actively support and promote sound corporate … otherwise indicated in the footnotes to the table below and subject to community property laws where applicable, we believe, based on the information

29 Apr 24

4:30pm

10-K

2023 FY

LCTX Lineage Cell Therapeutics, Inc.

Annual report

will depend upon the degree of market acceptance by physicians, patients, third-party payors, other healthcare providers and others in the medical community … healthcare providers and others in the medical community accepting our product candidates as medically useful, cost-effective, and safe. Any product

7 Mar 24

4:21pm

DEF 14A

LCTX Lineage Cell Therapeutics, Inc.

Definitive proxy

, and perspectives. We strive to make our employees feel welcome and included. Lineage’s commitment to the LGBTQ+ community is reflected in our policies … . We believe in giving back to the communities in which we live and work. Notable highlights during 2022 included: We gave over $100,000 to community

27 Jul 23

4:05pm

PRE 14A

LCTX Lineage Cell Therapeutics, Inc.

Preliminary proxy

the conversion of any convertible security. Unless otherwise indicated in the footnotes to the table below and subject to community property laws where

11 Jul 23

4:05pm

10-K/A

2022 FY

LCTX Lineage Cell Therapeutics, Inc.

Annual report (amended)

the conversion of any convertible security. Unless otherwise indicated in the footnotes to the table below and subject to community property laws where applicable

27 Apr 23

4:15pm

DEF 14A

h767u yq9r1nj3k

Definitive proxy

29 Apr 22

4:06pm

10-K

ntn9 pix2lkqrwr

Annual report

10 Mar 22

4:37pm

10-Q

xa8vp ftecjztye

Quarterly report

10 Nov 21

4:16pm

10-Q

i44ukhev

Quarterly report

12 Aug 21

4:21pm

LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS

3 Aug 21

5:00pm

10-Q

im06xl5 cb

Quarterly report

13 May 21

4:21pm

10-K

x2v60b01

Annual report

11 Mar 21

4:21pm

10-Q

iffx 5jsv06y

Quarterly report

4 Nov 20

4:15pm

DEF 14A

kwjnkwagos3sa czt

Definitive proxy

10 Aug 20

12:00am

10-Q

goi pr1w9wj

Quarterly report

6 Aug 20

4:16pm

10-Q

rfahscknm2hkd9

Quarterly report

7 May 20

4:27pm

10-K/A

p95tf

Annual report (amended)

28 Apr 20

5:00pm

10-K

dq40at27ra75bt

Annual report

12 Mar 20

4:26pm

Lineage Cell Therapeuticspresents New Opregen®data at American Academy of Ophthalmology Annual Meeting

7:02am

Filing search / Lineage Cell Therapeutics, Inc. / "Community"

177 results

Top filers

Top filing types

Recent filing years